Pyoderma gangrenosum is different in different people, but the classic form has these typical features: It starts as one or more small red bumps that look like a rash or an insect bite. Very ...

Cite this: Pyoderma Gangrenosum: Pain Identified as Reliable Patient-Reported Outcome - Medscape - Sep 21, 2023. Comments. Commenting is limited to medical ...

Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with the general population, according to a cohort study. “Pyoderma gangrenosum is a ...

Pain as a patient-reported outcome measure during the treatment of pyoderma gangrenosum may indicate whether a patient is responding to treatment, according to a research letter published in JAMA ...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program ...

The discovery of VEXAS syndrome was reported in 2020, in which Beck et al characterized the rare, often life-threatening syndrome.The group identified 25 men with somatic mutations affecting ...

InflaRx has taken the difficult decision to abandon its drug development programme, vilobelimab, for rare inflammatory skin disorder pyoderma gangrenosum (PG), a move that has pummelled its share ...

InflaRx (NASDAQ:IFRX) lost over half of its market cap in the premarket on Wednesday after the German biotech announced it would discontinue studies into its lead candidate, vilobelimab, against a ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...

SPOKANE, Wash. – Ryan Becker, a Spokane resident, is battling an extremely rare skin condition known as pyoderma gangrenosum. After visits to the Mayo Clinic and Johns Hopkins, Becker has been ...